NYSE:ABBV - AbbVie Stock Price, News & Analysis

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie declared a quarterly dividend on Thursday, June 20th. Stockholders of record on Monday, July 15th will be paid a dividend of $1.07 per share on Thursday, August 15th. This represents a $4.28 annualized dividend and a dividend yield of 6.34%. The ex-dividend date of this dividend is Friday, July 12th. View AbbVie's Dividend History.

AbbVie announced that its Board of Directors has initiated a share buyback plan on Thursday, December 13th 2018, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 3.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings data on Friday, July, 26th. The company reported $2.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.21 by $0.05. The firm had revenue of $8.26 billion for the quarter, compared to analyst estimates of $8.09 billion. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The company's revenue for the quarter was down .3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.00 earnings per share. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AbbVie.

AbbVie updated its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share (EPS) guidance of $8.82-8.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.78.

14 brokerages have issued twelve-month price targets for AbbVie's stock. Their predictions range from $66.61 to $135.00. On average, they anticipate AbbVie's stock price to reach $91.3842 in the next twelve months. This suggests a possible upside of 35.3% from the stock's current price. View Analyst Price Targets for AbbVie.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

News coverage about ABBV stock has been trending positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AbbVie earned a news impact score of 2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for AbbVie.

AbbVie saw a increase in short interest during the month of July. As of July 15th, there was short interest totalling 44,168,500 shares, an increase of 56.6% from the June 15th total of 28,212,900 shares. Based on an average daily trading volume, of 9,230,000 shares, the short-interest ratio is currently 4.8 days. Approximately 3.0% of the company's stock are sold short. View AbbVie's Current Options Chain.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Zoetis (ZTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD).

AbbVie's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.22%), BlackRock Inc. (6.65%), Northern Trust Corp (1.36%), Bank of New York Mellon Corp (1.07%), Nuveen Asset Management LLC (0.65%) and State Farm Mutual Automobile Insurance Co. (0.60%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Parnassus Investments CA, Bank of Montreal Can, King Luther Capital Management Corp, Conning Inc. and First Trust Advisors LP. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez and William J Chase. View Insider Buying and Selling for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, BlackRock Inc., Putnam Investments LLC, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Man Group plc, Panagora Asset Management Inc. and Mackenzie Financial Corp. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Jeffrey Ryan Stewart, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $67.54.

AbbVie has a market capitalization of $99.86 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.